Plasticity of seven-transmembrane-helix receptor heteromers in human vascular smooth muscle cells

Lauren J. Albee\textsuperscript{1a}, Xianlong Gao\textsuperscript{2}, Matthias Majetschak\textsuperscript{2,3}*

\textsuperscript{1} Department of Surgery, Burn and Shock Trauma Research Institute, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States of America, \textsuperscript{2} Department of Surgery, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America, \textsuperscript{3} Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America

\* majetschak@usf.edu

Abstract

Recently, we reported that the chemokine (C-X-C motif) receptor 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3) heteromerize with $\alpha_{1A/B/D}$-adrenoceptors (ARs) and arginine vasopressin receptor 1A (AVPR1A) in recombinant systems and in rodent and human vascular smooth muscle cells (hVSMCs). In these studies, we observed that heteromerization between two receptor partners may depend on the presence and the expression levels of other partnering receptors. To test this hypothesis and to gain initial insight into the formation of these receptor heteromers in native cells, we utilized proximity ligation assays in hVSMCs to visualize receptor-receptor proximity and systematically studied how manipulation of the expression levels of individual protomers affect heteromerization patterns among other interacting receptor partners. We confirmed subtype-specific heteromerization between endogenously expressed $\alpha_{1A/B/D}$-ARs and detected that AVPR1A also heteromers with $\alpha_{1A/B/D}$-ARs. siRNA knockdown of CXCR4 and of ACKR3 resulted in a significant re-arrangement of the heteromerization patterns among $\alpha_{1}$-AR subtypes. Similarly, siRNA knockdown of AVPR1A significantly increased heteromerization signals for seven of the ten receptor pairs between CXCR4, ACKR3, and $\alpha_{1A/B/D}$-ARs. Our findings suggest plasticity of seven transmembrane helix (7TM) receptor heteromerization in native cells and could be explained by a supramolecular organization of these receptors within dynamic clusters in the plasma membrane. Because we previously observed that recombinant CXCR4, ACKR3, $\alpha_{1a}$-AR and AVPR1A form hetero-oligomeric complexes composed of 2–4 different protomers, which show signaling properties distinct from individual protomers, re-arrangements of receptor heteromerization patterns in native cells may contribute to the phenomenon of context-dependent GPCR signaling. Furthermore, these findings advise caution in the interpretation of functional consequences after 7TM receptor knockdown in experimental models. Alterations of the heteromerization patterns among other receptor partners may alter physiological and pathological responses, in particular in more complex systems, such as studies on the function of isolated organs or in in vivo experiments.
Introduction

Seven-transmembrane-helix (7TM) receptors, of which the majority are G protein-coupled receptors (GPCRs), play essential roles in many aspects of human physiology and in numerous disease processes. GPCRs are important drug targets, and a large proportion of Federal Drug Administration approved drugs are agonists or antagonists of various GPCRs [1, 2].

While GPCRs were originally thought to function as individual protomers or homodimers, accumulating evidence suggests that many GPCRs can also form heterodimers or hetero-oligomers with other receptor partners, which exhibit pharmacological properties distinct from the individual protomers [3–9].

Chemokine (C-X-C motif) receptor 4 (CXCR4), which is a prototypical GPCR, has been reported to exist as a monomer, dimer, and within nanoclusters comprised of more than three protomers in cells [10, 11]. Moreover, CXCR4 has been shown to form heteromers with multiple other GPCRs, such as chemokine (C-C motif) receptor 2 (CCR2), CCR5, CXCR3, atypical chemokine receptor (ACKR) 3, chemerin receptor 23, β2-adrenergic receptor (AR), δ-opioid receptor, cannabinoi receptor 2, protease-activated receptor 1, or the virally-encoded GPCR of Herpesvirus saimiri, which is thought to alter the pharmacological properties of the receptor partners [7, 12–21]. We showed previously that CXCR4 and ACKR3 also heteromerize with α1A/B/D-ARs and arginine vasopressin receptor 1A (AVPR1A) in recombinant systems and in rodent and human vascular smooth muscle cells (hVSMCs), through which the receptors cross-talk [9, 22–27]. Furthermore, we observed that siRNA knockdown of ACKR3 leads to significant increases of CXCR4:AVPR1A heteromers in the rat aortic smooth muscle cell line A7r5 and in hVSMCs [25], which could point toward interdependency of receptor-receptor interactions in the plasma membrane, i.e. that heteromerization between two receptor partners depends on the presence and the expression levels of other partnering receptors. To test this hypothesis and to gain initial insight into the formation of these receptor heteromers in native cells, we utilized proximity ligation assays (PLA) to visualize receptor-receptor proximity at single molecule resolution [28] and systematically studied how manipulation of the expression levels of individual protomers affect heteromerization patterns among other interacting receptor partners. Although PLA does not provide direct evidence for receptor-receptor interactions, positive signals for protein-protein proximity suggest receptor localization within a distance that is likely to permit direct interactions. The findings of the present study suggest that the heteromerization patterns among CXCR4, ACKR3, α1A/B/D-ARs, and AVPR1A are interdependent and demonstrate plasticity of their heteromerization patterns.

Materials and methods

Cell culture

hVSMCs (primary aortic smooth muscle cells, ATCC PCS-100-012) were purchased from American Type Culture Collection. As described previously [24, 25], hVSMCs were cultured in vascular basal media (ATCC PCS-100-030) supplemented with the vascular smooth muscle growth kit (ATCC PCS-100-042), containing 100 U/mL penicillin, and 100 μg/mL streptomycin. hVSMCs were used between passages 2–5.

Proximity Ligation Assays (PLAs)

PLAs were performed as described in detail previously [22–25, 29]. In brief, hVSMCs were grown and fixed on 16-well chamber slides (Nunc). Cells were fixed with 4% (wt/vol) paraformaldehyde for 15 min at room temperature and then blocked overnight at 4°C with 3% (wt/vol) BSA in PBS. To visualize proteins individually, slides were incubated with rabbit anti-AVPR1A (Bios BS-11598R), mouse anti-ACKR3 (R&D MAB42273), goat anti-CXCR4

Competing interests: The authors have declared that no competing interests exist.
(Abcam Ab1670) or rabbit anti-CXCR4 (Alomone Labs ACR-014), mouse anti-\(\alpha_{1A}\)-AR (Abcam Ab87990) or rabbit anti-\(\alpha_{1A}\)-AR (Abcam Ab137123), rabbit anti-\(\alpha_{1B}\)-AR (Abcam Ab169523) or goat anti-\(\alpha_{1B}\)-AR (Santa Cruz SC27136), and goat anti-\(\alpha_{1D}\)-AR (Santa Cruz SC27099) at 37˚C for 105 min in a humidifying chamber. To visualize receptor–receptor interactions, slides were incubated with a combination of two antibodies raised in differing species as appropriate at 37˚C for 105 min in a humidifying chamber. All antibodies were used in dilutions of 1: 500. Slides were then washed with PBS and incubated for 60 min at 37˚C in a humidifying chamber with secondary species-specific antibodies conjugated with plus and minus Duolink II PLA probes (1:5), as appropriate. Negative control slides were incubated with omission of one primary antibody and two differing species-specific secondary antibodies. Slides were washed again with PLA wash buffer A (Duolink II) and then incubated with ligation-ligase solution for 30 min at 37˚C in a humidifying chamber and also washed with PLA wash buffer A. Finally, slides were incubated with amplification polymerase solution for 100 min at 37˚C in a humidifying chamber. Slides were then washed twice with PLA wash buffer B (Duolink II), once with 0.01× PLA wash buffer B and allowed to dry. Slides were then mounted with a minimal volume of Duolink II mounting medium with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) overnight, and PLA signals (Duolink In Situ Detection Reagent Red (\(\lambda_{\text{excitation/emission}}\) 598/634 nm) were identified as fluorescent spots under a fluorescence microscope (Carl Zeiss Axiovert 200M with EC Plan-Neofluor objective lenses (40 × /1.30 oil) equipped with Axio CamMRc5 (Carl Zeiss) and AxioVision Rel. 4.9.1 (Carl Zeiss) acquisition software) at room temperature. For each vision field 10 z-stack images in 1 μm sections were acquired and compressed. PLA signals were quantified using the Duolink Image Tool software (Sigma-Aldrich). Images were imported in merged.tif formats containing both signal and nuclei channels. Merged images were visually verified for analytical quality. Comparisons and statistical analyses were performed only when PLA assays were performed on the same day in parallel experiments, and fluorescence microscopy was performed with the identical settings. For each experiment and condition, 10 randomly selected non-overlapping vision fields were analyzed.

**Gene silencing via RNA interference**

AVPR1A, CXCR4, and ACKR3 siRNA gene silencing was performed as described previously [22, 24, 25, 30]. In brief, hVSMCs were grown in 2 ml Accell siRNA delivery media per well (Dharmacon) in six-well plates (Nunc). Commercially available Accell AVPR1A, CXCR4, or ACKR3 siRNA was reconstituted with 1× siRNA buffer to a stock concentration of 100 μM. Cells were then transfected with 1 μM siRNA and incubated for 72 h at 37˚C, 5% CO2. Accell NT-siRNA pool was used as a negative control. After 72 h, cells were assayed for receptor cell surface expression.

**Data analyses**

Data are expressed as mean ± standard error. Student's t-test or One-way analyses of variance (ANOVA) with Dunnett's multiple comparison post hoc test for multiple comparisons were used to assess statistical significance, as appropriate. A two-tailed \(p<0.05\) was considered significant. All analyses were calculated with the GraphPad Prism 8, Version 8.4.0 software.

**Results and discussion**

**Heteromerization between AVPR1A and \(\alpha_{1}\)-AR subtypes**

We showed previously that CXCR4 and ACKR3 heteromerize with \(\alpha_{1A/B/D}\)-ARs and AVPR1A in recombinant systems and in hVSMCs [22–26]. Furthermore, we previously observed that
recombinant AVPR1A interacts with all recombinant α1-AR subtypes, as assessed by intermolecular bioluminescence energy transfer assays in HEK293T cells [9]. Because heteromerization between endogenously expressed AVPR1A and α1A/B/D-ARs has not been reported, we first tested whether AVPR1A heteromerizes with any of the α1-AR subtypes in hVSMCs. Consistent with our previous findings [22, 24, 25], AVPR1A and all α1-AR subtypes could be visualized in hVSMCs when PLA was performed to detect each protomer individually (Fig 1A and 1B). When PLA was performed to detect protein-protein interactions, we observed that AVPR1A constitutively heteromerizes with α1A-AR, α1B-AR, and α1D-AR (Fig 2A and 2B), which confirms our previous findings in a recombinant system.

Homodimerization of α1a/b/d-ARs and heterodimerization of α1b-AR with α1a-AR and α1d-AR has previously been observed in co-immunoprecipitation experiments with epitope-tagged recombinant receptors [31]. To confirm these observations in native cells, we screened for interactions between α1A/B/D-ARs. As shown in Fig 3A and 3B, we observed positive PLA signals for proximity between α1A-AR and α1B-AR, and for proximity between α1B-AR and α1D-AR (p < 0.01 vs. ctrl. for both). PLA signals for proximity between α1A-AR and α1D-AR were not significantly different from negative control PLA signals (p = 0.17), which is in agreement with previous findings in a recombinant system [31].

Re-organization of heteromers between α1A/B/D-ARs upon depletion of CXCR4 and ACKR3

Because CXCR4 and ACKR3 heteromerize with α1A/B/D-ARs in hVSMCs, we tested whether depletion of CXCR4 or ACKR3 from the cell surface by gene silencing via RNA interference influences the heteromerization patterns between α1A/B/D-ARs. We showed previously that
siRNA knockdown of CXCR4 or ACKR3 does not influence cell surface expression levels of $\alpha_{1A/B/D}$-AR in hVSMCs [22, 24]. As compared with cells incubated with non-targeting (NT)-siRNA, PLA signals for CXCR4 were reduced by 85% after incubation with CXCR4-siRNA (PLA signals/cell: NT-siRNA – 170 ± 16; CXCR4-siRNA: 26 ± 3; $p < 0.01$), and for ACKR3 by 75% after incubation with ACKR3-siRNA (PLA signals/cell: NT-siRNA – 53 ± 10; ACKR3-siRNA: 13 ± 1.5; $p < 0.01$), respectively (Fig 4A–4C).

Fig 2. AVPR1A heteromerizes with $\alpha_{1A/B/D}$-ARs in hVSMCs. (A) Representative PLA images for the detection of receptor–receptor interactions. Images show merged PLA/4',6-diamidino-2-phenylindole dihydrochloride (DAPI) signals. Ctrl: Omission of one primary antibody. Scale bar = 10 μm. (B) Quantification of PLA signals from n = 4 independent experiments with n = 10 images per experiment. *: $p < 0.05$ vs. ctrl. https://doi.org/10.1371/journal.pone.0253821.g002

Fig 3. $\alpha_1$-ARs form heteromeric complexes in hVSMCs. (A) Representative PLA images for the detection of receptor–receptor interactions. Images show merged PLA/4',6-diamidino-2-phenylindole dihydrochloride (DAPI) signals. Ctrl: Omission of one primary antibody. Scale bar = 10 μm. (B) Quantification of PLA signals from n = 3 independent experiments with n = 10 images per experiment. *: $p < 0.05$ vs. ctrl. https://doi.org/10.1371/journal.pone.0253821.g003
We observed that depletion of CXCR4 from the cell surface significantly reduced PLA signals corresponding to \( \alpha_{1A} \)-AR: \( \alpha_{1B} \)-AR heteromers, but did not affect PLA signals for \( \alpha_{1B} \)-AR: \( \alpha_{1D} \)-AR or \( \alpha_{1A} \)-AR: \( \alpha_{1D} \)-AR heteromers (Figs 5 and 6). In contrast, depletion of ACKR3 from the cell surface did not affect PLA signals for \( \alpha_{1A} \)-AR: \( \alpha_{1B} \)-AR heteromers, but significantly increased PLA signals for \( \alpha_{1B} \)-AR: \( \alpha_{1D} \)-AR and \( \alpha_{1A} \)-AR: \( \alpha_{1D} \)-AR heteromers (Figs 5 and 6). These observations suggest that ACKR3 and \( \alpha_{1D} \)-AR compete for heteromerization interfaces with \( \alpha_{1A} \)-AR and \( \alpha_{1B} \)-AR, which are occupied by \( \alpha_{1D} \)-AR upon depletion of ACKR3. The finding that CXCR4 knockdown reduces \( \alpha_{1A} \)-AR: \( \alpha_{1B} \)-AR heteromers, however, could be explained by a higher-order receptor complex, in which CXCR4 facilitates proximity between \( \alpha_{1A} \)-AR and \( \alpha_{1B} \)-AR.

**Re-organization of heteromers between \( \alpha_{1A/B/D} \)-ARs, CXCR4, and ACKR3 upon depletion of AVPR1A in hVSMCs**

Because our previous studies, in combination with the findings of the present study, suggest that AVPR1A heteromerizes with each of the CXCR4, ACKR3, and \( \alpha_{1A/B/D} \)-AR protomers in hVSMCs, we tested whether depletion of AVPR1A from the cell surface would also affect heteromerization patterns between all other receptor pairs. As compared with hVSMCs incubated with NT siRNA, PLA signals for AVPR1A in hVSMCs after incubation with AVPR1A siRNA were reduced by 66±4% (Fig 7A and 7B). PLA signals for ACKR3, CXCR4, and \( \alpha_{1A/B/D} \)-ARs were indistinguishable in hVSMCs incubated with AVPR1A-siRNA and NT-siRNA (Fig 7A and 7B).

---

**Fig 4. siRNA knockdown of CXCR4 and ACKR3 in hVSMCs.**

(A) Representative PLA images for the detection of CXCR4 in hVSMC after incubation with non-targeting (NT) or CXCR4 siRNA. Images show merged PLA/4',6-diamidino-2-phenylindole dihydrochloride (DAPI) signals. (B) Representative PLA images for the detection of ACKR3 in hVSMC after incubation with NT or ACKR3 siRNA. Images show merged PLA/4',6-diamidino-2-phenylindole dihydrochloride (DAPI) signals. Scale bar = 10 μm. (C) Quantification of PLA signals for the detection of CXCR4 and ACKR3 after incubation with siRNA, as in A/B. N = 3 independent experiments with n = 10 images per experiment. *: p<0.05 vs. cells incubated with NT siRNA.

https://doi.org/10.1371/journal.pone.0253821.g004
Quantification of the PLA signals for all combinations of heteromeric complexes between ACKR3, CXCR4, and $\alpha_{1A/B/D}$-ARs showed significant increases after incubation with AVPR1A siRNA for the following receptor pairs, as compared with hVSMCs incubated with NT-siRNA (Figs 8 and 9): CXCR4: $\alpha_{1A}$-AR– 91±38%; CXCR4: $\alpha_{1B}$-AR– 72±30%; ACKR3: $\alpha_{1A}$-AR– 91±25%; $\alpha_{1A}$-AR: $\alpha_{1B}$-AR– 101±17%; $\alpha_{1A}$-AR: $\alpha_{1D}$-AR– 141±29%; CXCR4: ACKR3– 59±21%. PLA signals suggestive of heteromerization between CXCR4 and $\alpha_{1D}$-AR and between ACKR3 and $\alpha_{1B/D}$-ARs were not significantly affected by AVPR1A knockdown.

Our observations further support the concept that heteromeric receptor complexes exist in a dynamic equilibrium on the cell surface, in which depletion of one receptor heteromerization partner leads to the re-arrangement of multiple heteromeric receptor complexes among other partnering receptors [24, 25]. Such a behavior is in agreement with previous studies of recombinant $\beta_2$-AR and CXCR4, which were found to exist in a dynamic equilibrium of monomers, dimers, and higher-order homomers in the plasma membrane [10, 32] and with our previous findings that peptides derived from transmembrane domains of ACKR3 interfere with CXCR4:ACKR3 heteromerization but increase ACKR3: $\alpha_{1A}$-AR, CXCR4: $\alpha_{1A}$-AR, and CXCR4: $\alpha_{1B}$-AR heteromers [24]. The finding that changes in PLA signals for the various heteromers after AVPR1A knockdown differed largely among the various receptor pairs could be

---

Fig 5. Detection of $\alpha_{1A/B/D}$-AR heteromers after depletion of CXCR4 or ACKR3 in hVSMCs. Representative PLA images for the detection of $\alpha_{1A/B/D}$-AR heteromers in hVSMCs after incubation with non-targeting (NT) siRNA (left), CXCR4 siRNA (center), or ACKR3 siRNA (right). Ctrl: Omission of one primary antibody. Images show merged PLA/4',6-diamidino-2-phenylindole dihydrochloride (DAPI) signals. Scale bar = 10 μm.

https://doi.org/10.1371/journal.pone.0253821.g005
attributed to differences in their abundance on the cell surface, in their interaction affinities for each other, and by differences in their relative position to each other within the plasma membrane.

Conclusions

Taken together, our findings on heteromerization between $\alpha_1$-AR subtypes and on heteromerization between AVPR1A and $\alpha_1$-AR subtypes in hVSMCs in the present study confirm previous observations in recombinant expression systems and validate that findings on these recombinant receptors are applicable to their endogenously expressed counterparts. Furthermore, we demonstrate interdependency of the heteromerization patterns among six distinct endogenously expressed 7TM receptor protomers. Irrespective of the underlying molecular mechanisms, these findings suggest plasticity of 7TM receptor heteromerization in native cells and could be explained by a supramolecular organization of these receptors within dynamic clusters in the plasma membrane. The latter is consistent with our recent findings in recombinant systems and with the idea that such receptor hetero-oligomers form larger and possibly metastable signaling complexes [8, 9].

The present study is limited in scope because it was not designed to explore functional consequences associated with the observed re-arrangements of the receptor heteromers. Nevertheless, functional cross-talk between $\alpha_1$-ARs and AVPR1A is well documented [33–35] and we reported functional consequences of hetero-oligomerization between CXCR4, ACKR3, $\alpha_1$-ARs and AVPR1A on the molecular, cellular, and organ levels previously [9, 22–26]. Thus, it appears possible that the re-arrangements of the receptor heteromerization patterns in

Fig 6. Re-organization of $\alpha_1$A/B/D-AR heteromers after depletion of CXCR4 or ACKR3 in hVSMCs. Quantification of PLA signals for the detection of receptor-receptor interactions in hVSMCs after incubation with non-targeting (NT) siRNA, CXCR4 siRNA, or ACKR3 siRNA, as in Fig 5. N = 3 independent experiments with n = 10 images per experiment. *: p<0.05 vs. cells incubated with NT siRNA.

https://doi.org/10.1371/journal.pone.0253821.g006
hVSMCs that we observed in the present study alter the pharmacological behavior of the individual receptor partners, which could contribute to the phenomenon of context-dependent GPCR signaling [36, 37].

In addition, our observations advise caution in the interpretation of functional consequences after GPCR knockdown in experimental models, because alterations of the
heteromerization patterns among other receptor partners may alter physiological and pathological responses, in particular in more complex systems, such as studies on the function of isolated organs or in in vivo experiments.

**Author Contributions**

**Conceptualization:** Xianlong Gao, Matthias Majetschak.

**Data curation:** Lauren J. Albee.

**Formal analysis:** Lauren J. Albee, Matthias Majetschak.

**Funding acquisition:** Matthias Majetschak.

**Investigation:** Lauren J. Albee.

**Methodology:** Lauren J. Albee, Xianlong Gao, Matthias Majetschak.

**Project administration:** Matthias Majetschak.

**Resources:** Xianlong Gao, Matthias Majetschak.

**Supervision:** Matthias Majetschak.

**Validation:** Lauren J. Albee.
Visualization: Lauren J. Albee, Matthias Majetschak.

Writing – original draft: Lauren J. Albee, Matthias Majetschak.

Writing – review & editing: Lauren J. Albee, Xianlong Gao, Matthias Majetschak.

References

1. Alexander SP, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol. 2017;174 Suppl 1:S17–S129. Epub 2017/10/22. https://doi.org/10.1111/bph.13875 PMID: 29055040; PubMed Central PMCID: PMC5650667.

2. Sharman JL, Benson HE, Pawson AJ, Lukito V, Mpamhanga CP, Bombail V, et al. IUPHAR-DB: updated database content and new features. Nucleic Acids Res. 2013;41(Database issue):D1083–8. Epub 2012/10/23. https://doi.org/10.1093/nar/gks960 PMID: 23087376; PubMed Central PMCID: PMC3531077.

3. Quitterer U, AbdAlla S. Discovering Pathologic GPCR Aggregation. Front Med (Lausanne). 2019;6:9. Epub 2019/02/15. https://doi.org/10.3389/fmed.2019.00009 PMID: 30761305; PubMed Central PMCID: PMC5395348.

4. Gaitonde SA, Gonzalez-Maeso J. Contribution of heteromerization to G protein-coupled receptor function. Curr Opin Pharmacol. 2017;32:23–31. Epub 2016/11/12. https://doi.org/10.1016/j.coph.2016.10.006 PMID: 27835800; PubMed Central PMCID: PMC5395348.

5. Franco R, Martinez-Pinilla E, Lanciego JL, Navarro G. Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization. Front Pharmacol. 2016;7:76. Epub 2016/04/12. https://doi.org/10.3389/fphar.2016.00076 PMID: 27065866; PubMed Central PMCID: PMC4815248.

6. Ferre S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, et al. Building a new conceptual framework for receptor heteromers. Nat Chem Biol. 2009;5(3):131–4. Epub 2009/02/17. https://doi.org/10.1038/nchembio0309-131 PMID: 19219011; PubMed Central PMCID: PMC2681085.

7. Gomes I, Ayoub MA, Fujita W, Jaeger WC, Pfleger KD, Devi LA. G Protein-Coupled Receptor Heteromers. Annu Rev Pharmacol Toxicol. 2016;56:403–25. Epub 2015/10/31. https://doi.org/10.1146/annurev-pharmtox-011613-135952 PMID: 26514203; PubMed Central PMCID: PMC5147582.

8. Sleno R, Hebert TE. Shaky ground—The nature of metastable GPCR signalling complexes. Neuropharmacology. 2019;152:4–14. Epub 2019/01/20. https://doi.org/10.1016/j.neuropharm.2019.01.018 PMID: 30659839.

9. Gao X, Enten GA, DeSantis AJ, Majetschak M. Class A G protein-coupled receptors assemble into functional higher-order hetero-oligomers. FEBS Lett. 2021;accepted for publication.

10. Martinez-Munoz L, Rodriguez-Frade JM, Barroso R, Sorzano COS, Torreno-Pina JA, Santiago CA, et al. Separating Actin-Dependent Chemokine Receptor Nanoclustering from Dimerization Indicates a Role for Clustering in CXCR4 Signaling and Function. Mol Cell. 2018;70(1):106–19 e10. Epub 2018/04/07. https://doi.org/10.1016/j.molcel.2018.02.034 PMID: 29625032.

11. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010;330(6007):1066–71. Epub 2010/10/12. https://doi.org/10.1126/science.1194396 PMID: 20929726; PubMed Central PMCID: PMC3074590.

12. Watts AO, van Lipzig MM, Jaeger WC, Seeber RM, van Zwam M, Vinet J, et al. Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes. Br J Pharmacol. 2013;168(7):1662–74. https://doi.org/10.1111/bph.12064 PMID: 23170857; PubMed Central PMCID: PMC3605874.

13. Sohy D, Yano H, de Nadai P, Urizar E, Guillabet A, Javitch JA, et al. Hetero-oligomerization of CCR2, CCR5, and the protean effects of “selective” antagonists. J Biol Chem. 2009;284(45):31270–9. Epub 2009/09/18. https://doi.org/10.1074/jbc.M109.054809 PMID: 19758998; PubMed Central PMCID: PMC2781525.

14. LaRocca TJ, Schwarzkopf M, Altman P, Zhang S, Gupta A, Gomes I, et al. beta2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. Journal of cardiovascular pharmacology. 2010;56(5):548–59. Epub 2010/08/24. https://doi.org/10.1097/FJC.0b013e3181f713fe PMID: 20729750; PubMed Central PMCID: PMC2978286.

15. de Poorter C, Baertsoen K, Lannoy V, Parmentier M, Springael JY. Consequences of ChemR23 heteromerization with the chemokine receptors CXCR4 and CCR7. PLoS One. 2013;8(2):e58075. https://doi.org/10.1371/journal.pone.0058075 PMID: 23469143; PubMed Central PMCID: PMC3585228.
16. Sohy D, Parmentier M, Springael JY. Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem. 2007; 282(41):30062–9. https://doi.org/10.1074/jbc.M705302200 PMID: 17715128.

17. Decaillot FM, Kazmi MA, Lin Y, Ray-Sahsa S, Sakmar TP, Sachdev P. CCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. The Journal of biological chemistry. 2011; 286(37):32188–97. Epub 2011/07/07. https://doi.org/10.1074/jbc.M111.277038 PMID: 21730085; PubMed Central PMCID: PMC3173186.

18. Pello OM, Martinez-Munoz L, Parrillas V, Serrano A, Rodriguez-Frade JM, Toro MJ, et al. Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur J Immunol. 2008; 38(5):537–49. https://doi.org/10.1002/eji.200737630 PMID: 18200497.

19. Coke CJ, Scarlet KA, Chetram MA, Jones KJ, Sandifer BJ, Davis AS, et al. Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression. J Biol Chem. 2016; 291(19):9991–10005. https://doi.org/10.1074/jbc.M115.712661 PMID: 26841863; PubMed Central PMCID: PMC4858902.

20. Evans AE, Tripathi A, LaPorte HM, Gao X, Volkman BF, Gaponenko V, Majetschak M. CXC chemokine receptor 4 signaling functions within hetero-oligomeric complexes with atypical chemokine receptor 3 and chemokine (C-X-C motif) receptor 4 in Vascular Smooth Muscle Cells. J Am Heart Assoc. 2017; 6(8):e006575. https://doi.org/10.1002/ijms.200737630 PMID: 18200497.

21. Gao X, Cheng YH, Enten GA, DeSantis AJ, Gaponenko V, Majetschak M. Regulation of the thrombin/ protease-activated receptor 1 axis by chemokine (CXC motif) receptor 4. J Biol Chem. 2020; 295(44):14839–905. Epub 2020/08/26. https://doi.org/10.1074/jbc.RA120.015355 PMID: 32839271; PubMed Central PMCID: PMC7606691.

22. Tripathi A, Vana PG, Chavan TS, Buweggermann LI, Byron KL, Tarasova NI, et al. Heteromerization of chemokine (C-X-C motif) receptor 4 with alpha1A/B-adrenergic receptors controls alpha1-adrenergic receptor function. Proc Natl Acad Sci U S A. 2015; 112(13):E1659–68. Epub 2015/03/17. https://doi.org/10.1073/pnas.1417563112 PMID: 25775258; PubMed Central PMCID: PMC4386352.

23. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nature methods. 2006; 3(12):995–1000. Epub 2006/10/31. https://doi.org/10.1038/nmeth947 PMID: 17072308.

24. Tripathi A, Davis JD, Staren DM, Volkman BF, Majetschak M. Asymmetrical ligand-induced cross-regulation of CXCR4/CXCR7 heterodimers in vascular smooth muscle. Open Biol. 2018; 8(1):170207. Epub 2018/02/02. https://doi.org/10.1098/rsob.170207 PMID: 29384606; PubMed Central PMCID: PMC5795052.

25. Gao X, Eby JM, Tripathi A, LaPorte HM, Gao X, Volkman BF, et al. Alpha1-adrenergic Receptors Function Within Hetero-Oligomeric Complexes With Atypical Chemokine Receptor 3 and Chemokine (C-X-C motif) Receptor 4 in Vascular Smooth Muscle Cells. J Am Heart Assoc. 2017; 6(8):e006575. Epub 2017/09/02. https://doi.org/10.1161/JAHA.117.006575 PMID: 28862946; PubMed Central PMCID: PMC5586474.

26. Saini V, Marchese A, Majetschak M, CXCR chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J Biol Chem. 2010; 285(20):15566–76. Epub 2010/03/17. https://doi.org/10.1074/jbc.M110.103408 PMID: 20228059; PubMed Central PMCID: PMC2865527.

27. Uberti MA, Hall RA, Minneman KP. Plasticity of 7TM receptor heteromers. J Biol Chem. 2003; 278(12):995–1000. Epub 2006/10/31. https://doi.org/10.1038/nmeth947 PMID: 17072308.

28. Uberti MA, Hall RA, Minneman KP. Subtype-specific dimerization of alpha 1-adrenoceptors: effects on receptor expression and pharmacological properties. Mol Pharmacol. 2003; 64(6):1379–90. Epub 2003/12/03. https://doi.org/10.1124/mol.64.6.1379 PMID: 14645668.
32. Calebiro D, Rieken F, Wagner J, Sungkaworn T, Zabel U, Borzi A, et al. Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc Natl Acad Sci U S A. 2013; 110(2):743–8. Epub 2012/12/26. https://doi.org/10.1073/pnas.1205798110 PMID: 23267088; PubMed Central PMCID: PMC3545784.

33. Bartelstone HJ, Nasmyth PA. Vasopressin Potentiation of Catecholamine Actions in Dog, Rat, Cat, and Rat Aortic Strip. Am J Physiol. 1965; 208:754–62. Epub 1965/04/01. https://doi.org/10.1152/ajplegacy.1965.208.4.754 PMID: 14274809.

34. Steppan J, Nyhan SM, Sikka G, Uribe J, Ahuja A, White AR, et al. Vasopressin-mediated enhancement of adrenergic vasoconstriction involves both the tyrosine kinase and the protein kinase C pathways. Anesth Analg. 2012; 115(6):1290–5. Epub 2012/08/14. https://doi.org/10.1213/ANE.0b013e3182691c11 PMID: 22886838.

35. Noguera I, Medina P, Segarra G, Martinez MC, Aldasoro M, Vila JM, et al. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery. Br J Pharmacol. 1997; 122(3):431–8. Epub 1997/11/14. https://doi.org/10.1038/sj.bjp.0701397 PMID: 9351498; PubMed Central PMCID: PMC1564956.

36. Niswender CM, Johnson KA, Miller NR, Ayala JE, Luo Q, Williams R, et al. Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol. 2010; 77(3):459–68. Epub 2009/12/23. https://doi.org/10.1124/mol.109.058768 PMID: 20026717; PubMed Central PMCID: PMC2835423.

37. Heuninck J, Perpina Viciano C, Isbilir A, Caspar B, Capoferri D, Briddon SJ, et al. Context-Dependent Signaling of CXC Chemokine Receptor 4 and Atypical Chemokine Receptor 3. Mol Pharmacol. 2019; 96(6):778–93. Epub 2019/05/17. https://doi.org/10.1124/mol.118.115477 PMID: 31092552.